Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 208-213

  Roberts, Ainslie L K ^a,b   Fletcher, Janice M ^a,b   Moore, Lynette ^a   Byers, Sharon ^a,b  

^a Department of Genetics and Molecular Pathology SA Pathology ^*  (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Glycosaminoglycans; Lysosomal storage disorder; Mucopolysaccharidosis type IIIA; Rhodamine B; Substrate deprivation

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARAN SULFATE; RHODAMINE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; GENE MUTATION; HISTOLOGY; LACTATION; LIVER FUNCTION TEST; LIVER METABOLISM; LOW DRUG DOSE; LYSOSOME STORAGE DISEASE; MOUSE; MUCOPOLYSACCHARIDOSIS; NEUROPATHOLOGY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SANFILIPPO SYNDROME TYPE A; SUBSTRATE DEPRIVATION THERAPY; THERAPY; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSAMINOGLYCANS; LITTER SIZE; LIVER; MICE; MUCOPOLYSACCHARIDOSIS III; PREGNANCY; RHODAMINES;

MURINAE; MUS;

EID: 77957226825     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.06.008     Document Type: Article

References (30)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease 2001, 3421-3452. McGraw-Hill Companies Inc., New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Bielicki J., Hopwood J.J., Melville E.L., Anson D.S. Recombinant human sulphamidase: expression, amplification, purification and characterization. Biochem. J. 1998, 329(Pt 1):145-150.
3. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
4. Hemsley K.M., King B., Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 2007, 90:313-328.
5. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 2004, 83:163-174.
6. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega J.J., O'Meara A., Cornu G., Souillet G., Frappaz D., et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995, 345:1398-1402.
7. Resnick J.M., Krivit W., Snover D.C., Kersey J.H., Ramsay N.K., Blazar B.R., Whitley C.B. Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation. Bone Marrow Transplant. 1992, 10:273-280.
8. Sivakumur P., Wraith J.E. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J. Inherit. Metab. Dis. 1999, 22:849-850.
9. Vellodi A., Young E., Cooper A., Lidchi V., Winchester B., Wraith J.E. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 1999, 22:638-648.
10. Roberts A.L., Rees M.H., Klebe S., Fletcher J.M., Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol. Genet. Metab. 2007, 92:115-121.
11. Roberts A.L., Thomas B.J., Wilkinson A.S., Fletcher J.M., Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res. 2006, 60:309-314.
12. Webb J.M., Hansen W.H. Studies of the metabolism of rhodamine B. Toxicol. Appl. Pharmacol. 1961, 3:86-95.
13. Webb J.M., Hansen W.H., Desmond A., Fitzhugh O.G. Biochemical and toxicologic studies of rhodamine B and 3,6-diaminofluroan. Toxicol. Appl. Pharmacol. 1961, 3:696-706.
14. Bonser G.M., Clayson D.B., Jull J.W. The induction of tumours of the subcutaneous tissues, liver and intestine in the mouse by certain dye-stuffs and their intermediates. Br. J. Cancer 1956, 10:653-667.
15. Hansen W.H., Fitzhugh O.G., Williams M.W. Subacute oral toxicity of nine D&C coal tar colors. J. Pharmacol. Exp. Ther. 1959, 122:29A.
16. Nainggolan-Sihombing G. The toxic effect of rhodamine B in rats. Paediatr. Indones. 1984, 24:125-138.
17. Dire D.J., Wilkinson J.A. Acute exposure to rhodamine B. J. Toxicol. Clin. Toxicol. 1987, 25:603-607.
18. Kelner M.J. Rhodamine B ingestion as a cause of fluorescent red urine. West. J. Med. 1985, 143:523-524.
19. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9:1389-1396.
20. Roberts A.L., Howarth G.S., Liaw W.C., Moretta S., Kritas S., Lymn K.A., Yazbeck R., Tran C., Fletcher J.M., Butler R.N., Byers S. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA. J. Cell. Physiol. 2009.
21. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal. Biochem. 1973, 54:484-489.
22. Harris E.H. Elevated liver function tests in type 2 diabetes. Clin. Diab. 2005, 23:115-119.
23. Zimran A., Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:961-966.
24. Piotrowska E., Jakobkiewicz-Banecka J., Baranska S., Tylki-Szymanska A., Czartoryska B., Wegrzyn A., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 2006.
25. A. Friso, R. Tomanin, M. Salvalaio, M. Scarpa, Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br. J. Pharmacol.
26. Malinowska M., Wilkinson F.L., Bennett W., Langford-Smith K.J., O'Leary H.A., Jakobkiewicz-Banecka J., Wynn R., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 2009, 98:235-242.
27. G. Wegrzyn, J. Jakobkiewicz-Banecka, M. Gabig-Ciminska, E. Piotrowska, M. Narajczyk, A. Kloska, M. Malinowska, D. Dziedzic, I. Golebiewska, M. Moskot, A. Wegrzyn, Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 38 695-701.
28. Piotrowska E., Jakobkiewicz-Banecka J., Tylki-Szymanska A., Liberek A., Maryniak A., Malinowska M., Czartoryska B., Puk E., Kloska A., Liberek T., Baranska S., Wegrzyn A., Wegrzyn G. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr. Ther. Res. 2008, 69:166-179.
29. Umeda M. Experimental study of xanthene dyes as carcinogenic agents. Gan 1956, 47:51-78.
30. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N. Engl J. Med. 2006, 354:731-739.